Back to Newsroom

Passage of the 21st Century Cures Act and its Potential Implications on Biodefense

SAN DIEGO, Dec. 21, 2016 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

Last week, President Obama signed the 21st Century Cures Act into law.  The $6.3 billion bill establishes new rules that direct the United States Food and Drug Administration (FDA) to approve drugs and devices with greater urgency.  Specific to medical devices, the Act requires the FDA to establish a priority review program for “breakthrough” devices, or for devices that target diseases for which no FDA-cleared or approved alternatives are available.

Click here to read the full release